ExodusPoint Capital Management’s Checkpoint Therapeutics CKPT Stock Holding History

ExodusPoint Capital Management’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,755	Closed	-$49K	–	1994
2022 Q1	$49K	Buy	2,755 +182	+7%	+$3.91K	﹤0.01%	2066
2021 Q4	$80K	Buy	2,573 +835	+48%	+$27.6K	﹤0.01%	1985
2021 Q3	$57K	Sell	1,738 -3,126	-64%	-$92.4K	﹤0.01%	1962
2021 Q2	$143K	Buy	4,864 +3,501	+257%	+$97K	﹤0.01%	2069
2021 Q1	$43K	Buy	+1,363	New	+$45.7K	﹤0.01%	2039
2020 Q2	–	Sell	-1,365	Closed	-$21K	–	1797
2020 Q1	$21K	Buy	+1,365	New	+$24.2K	﹤0.01%	1004
2019 Q2	–	Sell	-3,542	Closed	-$101K	–	1125
2019 Q1	$101K	Buy	+3,542	New	+$113K	0.01%	611

Other funds holding CKPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ExodusPoint Capital Management's CKPT Position: Q2 2022 in Review

ExodusPoint Capital Management sold out of Checkpoint Therapeutics (CKPT) in Q2 2022, closing a stake of 2,755 shares — an estimated $49K sold.

ExodusPoint Capital Management first reported a position in CKPT in Q1 2019 and held it in 7 quarters. The position peaked at $143K in Q2 2021. 62 funds tracked by Wall St. Rank hold CKPT as of Q2 2022.

ExodusPoint Capital Management reported no remaining Checkpoint Therapeutics position as of Q2 2022 after selling out during the quarter.
ExodusPoint Capital Management sold 2,755 Checkpoint Therapeutics shares in Q2 2022, an estimated $49K.
ExodusPoint Capital Management first reported a position in Checkpoint Therapeutics in Q1 2019 and held it in 7 quarters.
ExodusPoint Capital Management's Checkpoint Therapeutics position peaked at $143K in Q2 2021.
62 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.